西藏藥業(600211.SH):也在積極探索和挖掘藏藥的經典名方
格隆匯6月5日丨有投資者向西藏藥業(600211.SH)提問,“公司目前對外投資進度已經停滯,是否考慮重啟新藥研發?請問公司在生物藥領域有無新的方向?在中藥領域請問公司有無開發藏藥經典名方里的藥品?公司在藥物研發方面有何進展?”
西藏藥業回覆稱,按照發展戰略,公司一直都在積極採取收購已上市的成熟藥品、聯合研發等多種方式擴充產品線,增強公司的抗風險能力。在中藥領域,公司在對現有銷售品種進行再研究的同時,也在積極探索和挖掘藏藥的經典名方,以增加產品儲備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.